Updated:
Hansoh Pharmaceutical Group
Hansoh Pharmaceutical Group traces its origins to 1995, when Zhong Huijuan — then a chemistry teacher — founded a drug distribution business in...
Hansoh Pharmaceutical Group
Hansoh Pharmaceutical Group traces its origins to 1995, when Zhong Huijuan — then a chemistry teacher — founded a drug distribution business in Lianyungang, a coastal city in Jiangsu province. The company evolved from a regional state-owned distributor into a research-driven manufacturer, listing on the Hong Kong Stock Exchange in June 2019 in what was at the time the largest pharmaceutical IPO in the city's history. Zhong remains the controlling shareholder and chairwoman, while her daughter, Sun Yuan, serves as an executive director. The firm's strategic focus spans central nervous system (CNS) disorders, oncology, anti-infectives, and metabolic diseases. CNS products — particularly olanzapine and paliperidone — historically drove revenue, capturing dominant market share in China's antipsychotic segment. Oncology has become the sharpest growth vector, anchored by the third-generation EGFR inhibitor aumolertinib and multiple JAK-pathway assets. The company invests substantially in in-house R&D — 15-20% of revenue — alongside licensing deals with global firms like Viela Bio and Terns Pharmaceuticals. Hansoh operates primarily in mainland China, with generic and innovative portfolios distributed through a network covering more than 10,000 hospitals. Zhong Huijuan ranks consistently among Asia's wealthiest women, with Forbes estimating her net worth north of $10 billion. The family's pharmaceutical influence is unusual: her husband, Sun Piaoyang, founded Jiangsu Hengrui Medicine, China's largest oncology drugmaker by market capitalization. While Hansoh and Hengrui operate as separate publicly listed entities with distinct pipelines and governance structures, their shared domicile in Lianyungang and overlapping therapeutic areas draw significant investor scrutiny. In September 2023, the firm completed its first major overseas manufacturing acquisition, buying a sterile injectables facility in the United Kingdom to support international expansion. Hansoh represents a rare structural configuration: a single-family-controlled pharmaceutical group operating as a publicly listed entity without a separate formal family office vehicle. The Zhong-Sun family exercises control through a holding company, Sunrise Investment, creating a governance layer that bridges public-market accountability with concentrated family ownership. This hybrid model — part founder-led pharma company, part family-wealth steward — sits at the intersection of China's biotech ascent and its emerging family-office ecosystem.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Lianyungang
Corporate office
Lianyungang, Jiangsu, China
Principals
Zhong Huijuan
Founder and Chairwoman
Sun Yuan
Executive Director
Sector focus
Frequently asked questions
Who runs investment decisions at Hansoh's family office?
Hansoh does not operate a separately branded family office. The Zhong-Sun family's wealth is primarily held through controlling stakes in Hansoh Pharmaceutical and Jiangsu Hengrui Medicine. Strategic capital allocation — including M&A, R&D partnerships, and manufacturing investments — is executed through Hansoh's corporate treasury and executive leadership, chaired by Zhong Huijuan, rather than a distinct investment entity.
How is Hansoh related to Jiangsu Hengrui Medicine?
Hansoh founder Zhong Huijuan is married to Sun Piaoyang, the founder of Jiangsu Hengrui Medicine. Both are publicly listed Chinese pharmaceutical companies headquartered in Lianyungang, Jiangsu province. They maintain separate boards, management teams, and drug pipelines, though their overlapping therapeutic areas — particularly oncology — and shared family control create a unique dual-company pharma dynasty that draws close regulatory and investor attention.
Where does the underlying wealth come from?
The wealth originated from Zhong Huijuan's founding of Hansoh Pharmaceutical in 1995 as a state-owned drug distributor, which she later privatized and transformed into a publicly traded R&D-driven pharmaceutical manufacturer and distributor. Her equity stake, amplified by the company's 2019 Hong Kong IPO, established her as one of the world's wealthiest self-made women, with Forbes reporting a net worth exceeding $10 billion.
What is Hansoh's known posture on co-investments alongside external GPs?
Hansoh Pharmaceutical does not operate a disclosed fund-of-funds or co-investment program typical of institutional family offices. Its external capital deployment takes the form of strategic licensing agreements, joint ventures, and corporate acquisitions — such as the 2023 UK sterile injectables facility purchase — rather than LP commitments to external investment managers.
How does the family influence governance at a public company?
Zhong Huijuan exerts control through Sunrise Investment, the family's holding vehicle and Hansoh's majority shareholder. Her daughter, Sun Yuan, serves as an executive director, and the board composition reflects founder-family influence. This structure distinguishes Hansoh from widely held public companies by embedding concentrated voting power within a public-market framework.
Does the Zhong-Sun family maintain philanthropic structures?
Public record indicates the family participates in charitable giving, including donation pledges during public-health crises in China, but no dedicated family foundation or philanthropic entity with published governance, assets, or grant-making strategy is publicly disclosed as a formal vehicle of the Zhong-Sun family.
What is the geographic scope of Hansoh's investment activity?
Commercial operations center on mainland China, distributing generic and innovative drugs to over 10,000 hospitals. Internationalization is accelerating through targeted acquisitions — specifically the 2023 purchase of a UK manufacturing site — and out-licensing deals with global partners, signaling a nascent but deliberate geographic diversification strategy.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: